A Phase 1, Open-label, Dose-ranging Study to Assess the Safety, Tolerability, Preliminary Efficacy, and Dose Effect of Signature Cord Product in Patients With Symptomatic Osteoarthritis of the Knee
Latest Information Update: 07 Feb 2024
At a glance
- Drugs SIG 001 Arugula Sciences (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
Most Recent Events
- 09 Jan 2023 New trial record
- 04 Jan 2023 According to an Arugula Sciences media release, company received approval from US FDA for this trial.